Novosense Microelectronics 2025 Annual Report: Key Shareholder & Price-Sensitive Updates

Overview

Novosense Microelectronics (Suzhou Novosense Microelectronics Co., Ltd.), a leading Chinese fabless analog chip provider, has released its 2025 annual report. The report contains several updates that are important for shareholders and may have price-sensitive implications. This article summarizes the most pertinent disclosures and details from the report, focusing on financial performance, corporate governance, shareholding changes, and other developments that could potentially move the company’s share price.

1. Significant Losses and Dividend Suspension

• Net loss for 2025: The company reported a net loss attributable to shareholders of RMB 228.9 million for the year ended December 31, 2025, with an even larger net loss of RMB 286.3 million after deducting non-recurring profit or loss. This trend of significant losses is material and price-sensitive, as it could impact investor sentiment and valuation.
• No dividend payout: In light of the continued losses and negative retained earnings, the board has proposed not to distribute any profits, pay cash dividends, issue bonus shares, or increase share capital from capital reserves for 2025. This is in line with the company’s Articles of Association and regulatory requirements, given the negative net profit and accumulated losses in the parent company’s financial statements.
• Dividend Policy: The company maintains a general annual dividend policy prioritizing cash dividends (at least 10% of distributable profit, if specific conditions are met). However, due to losses, no dividends are declared for 2025.

2. Equity Incentives and Share-based Payments

• The company has implemented multiple employee shareholding platforms and equity incentive plans to attract and retain talent during its rapid development phase. However, the related share-based payment expenses have increased substantially and have had a notable negative impact on operating results. This is a key factor for investors, as high share-based payments can dilute earnings and affect share value.
• The company emphasizes that while equity incentives help retain core talent, the expense will continue to affect operating results in the foreseeable future.

3. Major Shareholding and Lock-up Undertakings

• Lock-up Restrictions: Directors, senior management, controlling shareholders, and associated entities are subject to strict lock-up arrangements on their shareholdings, typically prohibiting transfers for 36 months from listing, and in some cases, imposing restrictions for up to two years after the lock-up period. Transfers are capped at 25% per year thereafter, and additional price-based lock-up extensions can occur if the share price underperforms after listing.
• Price Stabilization Measures: The company has formal mechanisms to stabilize the share price, including potential share repurchases, and shareholding increases by controlling shareholders and management, should the share price fall below net asset value for 20 consecutive trading days. This is an important safeguard for shareholders, but also signals the company’s concern about possible price volatility.
• Strict Penalties for Breach: If directors, senior management, or controlling shareholders breach undertakings (e.g., by unauthorized share sales or failure to meet disclosure obligations), they may forfeit gains, face compensation claims, be banned from selling shares, be ineligible for dividends or incentives, and be compelled to issue public apologies.

4. H Share Issuance and Use of Proceeds

• H Share Listing: On December 8, 2025, Novosense issued 19,068,400 H Shares at HK\$116.00 per share, expanding the overseas investor base and potentially increasing liquidity.
• Use of Funds: The net proceeds from the H Share issuance will be allocated as follows:
  • 18% to foundational R&D and manufacturing platforms
  • 22% to expanding the product portfolio
  • 25% to overseas sales network and marketing
  • 25% to strategic investments and acquisitions
  • 10% to general corporate and working capital needs

  As of December 31, 2025, no proceeds had been utilized yet, with all funds expected to be deployed by December 31, 2030.

5. Share Capital Changes and Treasury Shares

• Share Repurchase: In January 2026, the company repurchased 521,686 A Shares, which are held as treasury shares. This move may signal management’s confidence in the company’s prospects or serve to support the share price.
• Share Structure: As of the end of 2025, the company had 161,596,833 shares in issue, with a significant increase due to the H Share offering.

6. Risk Factors Disclosed

• Inventory impairment risk: Expansion has led to increased inventory, raising the risk of impairment if market demand weakens or forecasts prove inaccurate.
• Gross margin risk: The company faces margin volatility due to price competition, product mix, and procurement costs.
• Exchange rate risk: As overseas operations expand, the exposure to currency fluctuations increases.
• Other risks: Persistent high share-based payments (from equity incentives) continue to affect profitability. The company had no material litigation, contingent liabilities, or significant contracts with controlling shareholders during the period.

7. Corporate Governance and Shareholder Communication

• Information Disclosure and Internal Controls: The company has adopted robust internal control and risk management systems, including policies to prevent insider trading and ensure timely disclosure of inside information. No material deficiencies were reported in 2025.
• Shareholder Engagement: The company maintains transparent communication channels, with annual meetings, investor briefings, and timely publication of corporate communications in both English and Chinese.
• Profit Distribution Policy: The company’s profit distribution policy prioritizes cash dividends, but payouts are highly conditional on profitability, positive retained earnings, and absence of major capex.

8. Undertakings and Penalties for Non-Compliance

• Strict compliance required: The report outlines severe consequences for failure to perform undertakings by management, shareholders, or the company itself. These include public apologies, forfeiture of ill-gotten gains, suspension of dividends or compensation, and, in extreme cases, transfer bans and legal action.
• Special provisions apply in the event of force majeure (e.g., regulatory changes, natural disasters).

9. Other Noteworthy Events

• No major acquisitions or disposals took place during 2025, aside from smaller partnership interest transfers in entities related to the semiconductor industry.
• No material litigation, contingent liabilities, or major credit events involving the company or its controlling shareholders were reported.
• Directors’ Interests: No director had any interest in a business competing with Novosense, nor did any director benefit from arrangements to acquire shares or debentures during the reporting period.

Conclusion: Key Share Price Drivers and Shareholder Takeaways

• Losses and No Dividend: The continued losses and suspension of dividends are likely to weigh on investor sentiment and share price in the near term.
• High Share-based Payments: Ongoing high equity incentive expenses could further dilute future earnings.
• Share Repurchase: The recent buyback of A Shares may offer some price support, depending on execution and market perception.
• Future Growth Plans: The sizeable cash pile from the H Share offering, earmarked for R&D, overseas expansion, and acquisitions, provides potential for longer-term growth—pending effective execution.
• Corporate Governance: The company’s strong emphasis on compliance, internal controls, and strict penalties for non-performance may reassure institutional investors.

Disclaimer: This article is a summary and analysis of the 2025 annual report of Suzhou Novosense Microelectronics Co., Ltd. for informational purposes only. It does not constitute investment advice. Investors are urged to review the full report and consult professional advisers before making any investment decisions. The author is not responsible for any losses arising from reliance on the information provided herein.

View NOVOSENSE Historical chart here